Telomerase reactivation induces progression of mouse Braf -driven thyroid cancers without telomere lengthening.

Mutations in the promoter of the telomerase reverse transcriptase ( ) gene are the paradigm of a cross-cancer alteration in a non-coding region. promoter mutations (TPMs) are biomarkers of poor prognosis in several tumors, including thyroid cancers. TPMs enhance transcription, which is otherwise silenced in adult tissues, thus reactivating a oncoprotein.